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Abstract
Background: Clinical reinfection with varicella is normally ignored in mathematical
transmission models as it is considered too rare to be important.
Methods: We apply basic bifurcation analysis to a simple mathematical model of
varicella-zoster virus (VZV) transmission incorporating reinfection.
Results: We demonstrate that under certain conditions this model can exhibit
periodic behaviour as opposed to what is observed in VZV models that ignore the
possibility of repeat varicella attacks. Periodicity can be induced by a combination of
immune boosting and reinfection while the impact of zoster (shingles) recurrence on
the onset of periodicity is negligible.
Conclusions: Our results suggest that mathematical models of VZV may benefit from
inclusion of repeat varicella.
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Background
Varicella-zoster virus (VZV) is first manifested as varicella (also known as chickenpox), a
rash that turns into open lesions. In the absence of vaccination, this usually happens when
a person is young. While the symptoms clear within a week or so, VZV remains latent
in the nervous system and may reactivate to cause a rash called herpes zoster (HZ) or
shingles. Why this reactivation happens remains unclear, although it is generally assumed
that onset is related to reduced levels of cellular immunity [1-3].
Clinical reinfection with varicella is thought to be rare and is typically not accounted
for in epidemiological models of VZV transmission [4]. However, observational studies
suggest that this may be inaccurate, with a number of literature reports suggesting that
reinfection occurs with moderate frequency. In particular, two US studies [5,6] based on
active surveillance data indicate that a substantial proportion of varicella cases (between
4.5% and 25%) report a prior history of varicella infection. A smaller study demonstrated
laboratory evidence of prior infection in 8 out of 115 (7%) patients with clinical varicella
infection [7]. There are also case reports of multiple varicella attacks in healthy children
[8]. Hence, it appears that prior infection does not always result in sustained protective
immunity against subsequent varicella reinfection and there is a case for considering this
process more closely in models.
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Repeat HZ attacks in immunocompetent individuals have also typically been excluded
in epidemiological modelling studies [4,9,10], under the assumption that repeat attacks
primarily occur in immunocompromised individuals. However, second attacks were
observed by Hope-Simpson [1] with 8 out of 192 cases recorded in his series being
a repeat event. Repeat cases were also observed by Wilson in a rural UK practice
with 6 out of 151 cases identified as repeat events [11]. More recently, a US study
found that 95 out of 1,669 individuals with a medically documented episode of HZ had
two or more attacks (8 individuals had three or more attacks) [12]. While immuno-
compromised patients had a higher incidence of recurrence, the rate of recurrence in
immunocompetent patients was similar to the rate of first attacks reported in other
studies.
The Hope-Simpson hypothesis that the immune response of someone who has been
exposed to varicella can be strengthened (boosted) via subsequent exposure to VZV
[1] has been supported by both clinical and modelling studies [3,13] although there
are studies which failed to observe evidence of boosting [14]. The degree of expo-
sure that would be required to provide an immune boost remains unknown. The VZV
modelling studies of which we are aware implement boosting by assuming that indi-
viduals with weakened immunity are boosted to full immunity at a fraction of the
rate of at which they would be becoming infected with varicella (this rate is often
referred to as a force of infection) [4,10,15-17]. In a recent work on the transmis-
sion of pertussis, the potential for the rate of boosting to exceed the force of infection
was explored and shown to induce both cyclical behaviour and the potential for dis-
ease recurrence following immunisation [18]. It was suggested that immune boost could
occur even if the exposure dose is too small to be likely to cause clinical infection.
This is supported by the observation that immune memory cells respond more rapidly
and to lower doses of antigen when primed through previous exposure than in naive
individuals [19,20].
In this paper, we consider a simple mathematical model of varicella-zoster virus
transmission incorporating clinical reinfection with varicella, immune boosting requir-
ing either more or less exposure to VZV than primary infection, and HZ recurrence.
Our aim is to investigate whether the behaviour of this model qualitatively changes
when its parameters are varied within ranges selected based on current knowledge of
VZV. Specifically, we are interested in identifying conditions whereby there is switch-
ing from stable equilibrium behaviour (that modelling studies normally focus on) to
periodic behaviour. While varicella is known to exhibit periodicity [3,21], the evidence
for HZ periodicity is still unclear, with studies both supporting periodically-varying
incidence [22,23] and failing to find evidence of it [24,25]. The majority of epidemiolog-
ical modelling studies have not explicitly incorporated periodic VZV transmission (e.g.
transmission rates modelled as sinusoid) or observed VZV-related periodicity, although
extensive investigations of this periodicity have been conducted in the context of chaotic
dynamics (see e.g. [26]).
Methods
We consider a compartmental model as illustrated schematically in Figure 1. This model
describes VZV transmission in a large population (i.e. transmission characteristics are
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Figure 1 Schematic diagram of a simple VZV model. The included compartments contain the susceptible to
varicella (S), individuals exposed to varicella (E), those who are infected with varicella (I), who have recovered
and are protected from VZV (R), who are weakly immune (W), i.e. individuals partly susceptible to varicella and
HZ, individuals infected with zoster (IZ) and those who have recovered from zoster and are immune to VZV
(RZ) and individuals who lost immunity after recovery from zoster and are susceptible to VZV (SZ). The arrows
indicate movements between compartments at the rates marked by Greek letters. The rates are explained in
Table 1.
averaged over large groups of individuals) and is adapted from the basic structure of exist-
ing varicella models but with some additional components. The model is of SEIR-type,
with these compartments corresponding to susceptible, exposed, infected or immune
to varicella infection individuals, respectively. The model also includes additional states
representing reduced immunity and susceptibility to zoster (W), infection with zoster
(IZ), recovery from zoster and immunity (RZ) and, finally, susceptibility to varicella and
zoster following the loss of immunity acquired after recovery from zoster (SZ). This struc-
ture is essentially identical to the basic set of states in the absence of vaccination in the
model of Brisson et al. [4], which has been used as the basis for a number of subsequent
studies [10,16,17]. However, we also introduce 4 additional features, which we describe in
turn here. First, we allow for recurrence of HZ, with residence in the state RZ set to be
temporary (it is permanent in the papers derived from [4]) with an exit rate parameter θ .
Second, we allow for individuals in the reduced immunity state W to be boosted at a rate
that is higher than the force of infection (i.e. the boosting weight parameter κ is allowed to
be > 1). This is based on the observation that individuals previously exposed to infection
make immune responses to lower infectious doses than naive individuals and is included
to test whether this can produce periodicity in varicella incidence. Finally, we make two
further changes that deal with repeated varicella infections. The first of these allows for
recurrence of varicella from the reduced immunity state W, a transition that is supported
by the evidence of second varicella attacks described in the introduction (proportional
to the varicella force of infection λ with relative hazard ζ ). The final change also allows
for new primary infection with varicella from the SZ state (with relative hazard α) which
does not appear implausible given rates of zoster recurrence. The latter suggest that loss
of immunity may be sufficient to experience a second primary VZV infection (although
we are not aware of any published data that would clearly support possibility of the SZ to
E transition).
As we aim tomake our model reasonably parsimonious to facilitate understanding of its
equilibrium behaviour in the presence of the above-mentioned new features, we assume
a very simple demography with a constant death rate μ in all states, which is balanced
by births so that the population size is conserved. This clearly makes our model less real-
istic but also reduces the number of model parameters by at least a dozen as compared
with age-stratified models (see, for example, [4]). Hence, the model is described by the
following system of nonlinear ordinary differential equations:
Korostil et al. Theoretical Biology andMedical Modelling  (2015) 12:6 Page 4 of 11
S˙ = −(λ + μ)S+ μ (1a)
E˙ = −(ω + μ)E+ λS + ζλW + αλSZ (1b)
I˙ = −(γ + μ)I+ ωE (1c)
R˙ = −(σ + μ)R+ κλW+ γ I (1d)
W˙ = −((κ + ζ )λ + η + μ)W+ σR (1e)
˙IZ = −(ρ + μ)IZ+ ηW+ δSZ (1f)
R˙Z = −(θ + μ)RZ+ ρIZ (1g)
S˙Z = −(δ + αλ + μ)SZ+ θRZ (1h)
where it is assumed that
S + E+ I+ R+ W+ IZ+ RZ+ SZ = 1,
and the varicella force of infection is defined as
λ = β(I+ pIZ). (2)
The system coefficients are described and supporting references supplied in Table 1.
The base values should be understood as some values from the specified ranges (i.e.
plausible values) convenient as the starting point for bifurcation analysis. Concretely, we
would like to be able to vary any parameter value keeping other parameters at their base
values to obtain an initial Hopf point. The base value for varicella transmission coefficient
β has been specified based on the reported average basic reproductive ratio (R0 = 6.5)
Table 1Model parameters
Parameter Notation Base value, refs. Range
Varicella transmission coefficient β 325 [27] 120–500
Rate of becoming infectious with varicella ω 26 [21] 20–32
the base value corresponds to the average latent period of≈ 14 days
Varicella recovery rate γ 50 [21] 40–60
the base value corresponds to the average infectious period of≈ 7.3 days
Loss of full immunity rate σ 0.10 [4,9,17] 0.0125–4.0
the base value corresponds to the average duration of “full” immunity of 10 years
Varicella force of infection reduction coefficient for those ζ 0.10 [assumed] 0.0–1.0
who become reinfected following clearance of varicella
Varicella force of infection reduction coefficient for those α 0.90 [assumed] 0.0–1.0
who become reinfected following HZ attack
Boosting coefficient κ 3.0 [assumed] 0.0–20.0
Birth/death rate μ 0.0122 [29] 0.01–0.05
the base value corresponds to the average life expectancy of≈ 82 years
HZ reactivation rate η 0.05 [4,15,17] 0.0001–2.0
HZ recovery rate ρ 52 [17] 46–58
the base value corresponds to the average infectious period of≈ 7 days
Rate of HZ reactivation after loss of immunity following recovery from HZ δ 0.01 [12,23] 0.00–0.10
Rate of loss of immunity to VZV after recovery from HZ θ 4.0 [assumed] 0.00–12.0
the base value corresponds to immunity lasting 3months on average
Relative VZV infectiousness of HZ p 0.001 [10,17] 0.00–0.10
All rates in this table are per year. Note that β and p are used to define the force of infection (2).
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for 11 European countries [27]. It can be easily verified (using, for example, the next
generation approach described in [28]) that for system (1)
R0 = ωβ
(ω + μ)(γ + μ) .
Hence, using the base values for ω,μ and γ provided in Table 1, we see that β ≈
325 year−1. The rate of loss of full immunity σ is unknown but attempts to estimate it
have been made previously, hence we cite three relevant modelling studies. We set a base
value for σ corresponding to the average duration of full immunity of 10 years and let
σ take a range of possible values from 0.0125 (“full” immunity for 80 years) to 4.0 (“full”
immunity for only 3 months). The boosting coefficient κ can be interpreted as a measure
of how much exposure is required for immune boosting as compared with that required
for primary infection.We allow it to vary from 0 to 20. The birth/death rateμ has been set
to correspond to the current Australian life expectancy at birth [29]. There are no readily
available data to directly inform parameter p, which characterises the contribution of HZ
to the varicella force of infection. Some VZV modelling studies have assumed that this
contribution is so small that it can be ignored [30] while others attempted to estimate it.
In particular, p = 5.4 × 10−7 was estimated in [4] and [16], while p = 3.11 × 10−6 was
estimated in [31]. A substantially larger value of 0.05 was used in [17]. Hence, we allow p
to vary between 0 and 0.1. The rate of HZ reactivation after loss of immunity following
recovery from HZ δ is allowed to take values between 0 (no reactivation) and 0.1. Loss of
immunity to VZV after recovery from HZ is characterised by parameter θ which ranges
from 0 (no loss of immunity) to 12.0 (immunity lost after only 1 month). Finally, parame-
ters ζ and α have been introduced to allow for reinfection with varicella. In the base case
we assume that α = 0.90 (i.e. the force of varicella infection on those who have recovered
from HZ is reduced by only 10% as compared to that on someone susceptible to primary
varicella infection) and allow α to take values from 0 (those who have had HZ cannot be
reinfected with varicella) to 1. The base value for α is high not due to epidemiological
considerations but because we determined that for substantially lower values of α system
(1) does not deviate from stable equilibrium behaviour no matter what values the other
parameters take. This is evident from the results presented in the next section. We set
the base case value for ζ at 0.1, which means that the force of varicella infection on those
who have recovered from varicella and have not had HZ is reduced by 90% as compared
to that on individuals susceptible to primary infection.
In order to detect the periodic dynamics we systematically searched for Hopf points
using the XPPAUT [32] bifurcation analysis software. A Hopf point is a point where a
bifurcation from a branch of stable equilibrium to a branch of periodic oscillation occurs
[33,34]. This point can be detected by varying a single model parameter while the other
parameters are kept fixed. Having found the Hopf point, we can investigate where it would
be if another parameter were given a different value. In this way we obtain a set of Hopf
points which form a so-called Hopf curve.
Results
We constructed the Hopf curves for all pairs of model parameters. Four examples of these
curves are shown in Figure 2 while the complete set of curves (78 figures in total) can be
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Figure 2 Hopf curves for selected parameter pairs: (a) β is a varicella transmission coefficient and ζ is a
varicella force of infection reduction coefficient for those who become reinfected following clearance of
varicella; (b) σ is a loss of full immunity rate and δ is a rate of HZ reactivation after loss of immunity following
recovery from HZ; (c) θ is a rate of loss of immunity to VZV after recovery from HZ and κ is a boosting
coefficient; (d) α is a varicella force of infection reduction coefficient for those who become reinfected
following HZ attack and η is a HZ reactivation rate. Shaded areas limited by these curves correspond to
periodic solutions of (1).
found in Additional file 1. The shaded areas in each plot represent regions of each two-
parameter space in which solutions are periodic (with other parameters fixed at base-case
values as in Table 1), while the complementary area corresponds to solutions converging
to a (globally) stable equilibrium. Example of solutions corresponding to either area are
shown in Figure 3.
time (years)

















Figure 3 Varicella and zoster incidences produced by (1) reach a steady equilibrium (i.e. they are both
straight lines) if ζ = 0.05, κ = 0.6,α = 0.01 and other parameter values are as in Table 1; if instead we take
ζ = 0.01, κ = 3.0,α = 0.95, varicella and zoster incidences exhibit a steady periodic behaviour.
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We found that for certain parameters it was easy to obtain periodic behaviour for most
or all of their values taken from within the ranges given in Table 1. Specifically, for all val-
ues of β under 400 we could normally observe oscillations, and this was also the case for
β under 500 when η and/or σ were increased or μ and/or ζ were decreased as compared
to their base values. This is illustrated in Figure 2a, where one can pick any value of β and
for that value there is always a range of values of ζ to select to ensure periodic behaviour.
For the rate of becoming infectious with varicella, ω, oscillations were possible for all val-
ues except when the HZ recovery rate ρ was at the bottom of its range (around 46-48) and
δ was approaching 0.017. Similarly, the entire range for the varicella recovery rate γ val-
ues allowed for oscillatory solutions except when δ and θ were varied. The HZ recovery
rate, ρ, behaved in the same way. Note that β ,ω, γ and ρ are considered well informed.
Another group of parameters turned out to be unnecessary to support oscillatory
behaviour. One of these parameters was ζ : it usually had to be under 0.02, i.e. the force of
varicella infection on those who cleared varicella previously had to be reduced by at least
98%. This means that ζ could as well be zero, as shown in Figure 2a. Parameter δ (the rate
of HZ reactivation following recovery from HZ) tended to be under 0.07 unless κ ,μ, ζ
and σ were manipulated. As shown in Figure 2b, δ can be as large as 0.1 if σ is somewhere
between 0.2 and 0.55, but it can also be zero. Similarly, p was consistent with oscilla-
tions when small (of the order 10−3) or equal to zero in line with the values estimated in
[4,16,31] but much less than p = 0.05 used in [17].
At last, there were six parameters that allowed for oscillatory behaviour when the ranges
of values they could vary in were narrowed to some extent. Specifically, the boosting
parameter κ had to exceed 2.5. Figure 2c illustrates that in the grey area where the values
of κ and θ corresponding to oscillations are, κ is clearly much larger than 1. Parameter
μ was restricted to under 0.015 (the corresponding life expectancy of at least 66.7 years)
unless η increased and then μ could even be 0.04. The loss of full immunity rate, σ , had
to exceed 0.1 (duration of immunity under 10 years) but was usually limited by 0.8 (or 1.1
if κ was approaching 8). The values of θ under about 2 or a little less were not compatible
with oscillations (see Figure 2c) and neither was the HZ reactivation rate η under 0.05,
which is evident from Figure 2d. At last, α had to be over 0.7 in most cases - a notable
exception is shown in Figure 2d where α can approach 0.3 assuming that η is around 0.5.
The period of oscillation itself tended to vary between 4 and 5 years for most parameter
combinations that are consistent with periodic solutions, which is illustrated in Figure 4.
We were unable to obtain solutions with a period close to 1 year using parameter val-
ues from the ranges given in Table 1. This period would be of interest because varicella
incidence has been reported to exhibit yearly peaks (see, for example, [23]).
It is pertinent to note that periodic solutions typically corresponded to repeat varicella
incidence that we would call substantial. For example, varying ζ while all other model
parameters are fixed results in detection of a Hopf point at ζ = 0.01314. This point
corresponds to the yearly incidence of repeat varicella periodically reaching a maximum
of 1.05% of the modelled population. The yearly HZ incidence is also periodic in this
circumstance averaging 0.00215% and peaking at around ±0.0023%.
Discussion
In this study, we developed a simple VZV transmission model with novel features to
explore the influence of boosting and disease recurrence on the potential for periodicity
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Figure 4 Changes in the period of steady oscillations for selected values of κ .
in varicella and zoster disease incidence.We relied upon bifurcation analysis of this model
to assess the relationship between key parameters and the existence of periodic solutions.
In comparison with other published VZV transmission models, our model has four
additional features: repeatedHZ attacks and rates of boosting exceeding the force of infec-
tion are allowed, while we also include the possibility of clinical reinfection with varicella
from a waned immunity state and in individuals who have experienced zoster.
We verified that our model can produce oscillations in both varicella and zoster which
is similar to the situation described in an extensive Japanese study covering a total of
48,388 patients with zoster [23]. However, some of the model features were shown to be
redundant in the context of periodicity (i.e. periodic solutions could still be obtained if
these features were removed from the model):
• reinfection with varicella for individuals who recovered from varicella and are in the
weakly immune state W (as mentioned in Results, ζ can be zero);
• reactivation of HZ following recovery from zoster (δ = 0 is possible);
• contribution of HZ to varicella force of infection (p can be zero).
On the other hand, the following requirements turned out essential to produce stable
periodic solutions:
• duration of full immunity to VZV is no longer than 10 years (σ > 0.1);
• duration of immunity to VZV following recovery from HZ should not exceed 6
months (θ > 2)
• immune boosting requires less exposure than primary varicella infection (κ ≥ 2.5);
• unless the average HZ reactivation rate η is only slightly under 0.2 (that is 4 times its
base value), those who have had HZ and are in contact with individuals infected with
varicella have little or no added protection against varicella as compared with
individuals never infected with VZV (α > 0.7).
It is not immediately clear how to assess plausibility of these requirements. The existing
data can only give some indications regarding the average time needed to return from I
to I or progress from I to IZ. Since the immunity in question is the full immunity corre-
sponding to the average time needed to progress from I to W and the latter is included
to implement the Hope-Simpson hypothesis (i.e. the very existence of this state is not an
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established fact), we should note that there is no data to suggest that σ > 0.1 may be
unrealistic. There is also not enough data to clarify the average duration of staying in the
RZ compartment.
The exposure required for boosting VZV immunity is not well understood but the
Hope-Simpson hypothesis is widely applied inmodelling studies with κ ≤ 1. Nonetheless,
we are not aware of any strong evidence in support of this restriction which precludes
κ ≥ 2.5 (a relevant discussion on why κ > 1 is likely to be valid for pertussis can be found
in [18]).
Based on the Hope-Simpson hypothesis, our model makes individuals recovered from
HZ immune but we do not know how long this immunity should last on average. Our
analysis shows that we can obtain periodicity if this duration is under 6 months which
we can not consider implausible until there is evidence to prove otherwise. One would
also expect that being in the post-zoster state individuals may be able to strengthen their
immunity when exposed to varicella and our results do not contradict this expectation.
However, they indicate that the onset of oscillatory behaviour would occur if this pro-
tection, if gained at all, were insignificant: α > 0.7 means that someone who have had
HZ, then was immune for a while and then became susceptible to VZV is becoming rein-
fected with varicella at an average rate reduced by up to 30% at best or much less, as
compared with a rate this individual would be becoming infected with varicella at if he
or she was exposed to varicella for the first time. As those who have had HZ are most
often elderly and their immunity is weakened by age, there is a reason to believe that they
may become susceptible to varicella reinfection via contact with infectious varicella cases
and the immune boosting mechanism may not work for these individuals very well. The
absence of a strong evidence base for such cases does not necessarily preclude them being
common. For example, routine reporting schemes are frequently recording numerous
“unspecified VZV” diagnoses [35] which could be either HZ or varicella. Separating vari-
cella and HZ diagnoses can be difficult. Laboratory testing is infrequent, and the ability
to differentiate re-infection from reactivation is therefore based on the disease syndrome
rather than confirmation through viral testing. As discussed by Volpi et al. [36] the clini-
cal diagnosis of HZ is subject to error, with the Shingles Prevention Study reporting that
24% of clinical HZ diagnoses were not confirmed to have HZ by laboratory testing [13]
and a UK study found 17% (48 out of 278) of GP clinical HZ diagnoses to be incorrect
[37]. Thus, while reinfection with varicella is suspected to be infrequent, confirmation of
this fact is difficult given errors in reporting and diagnosis.
Hence, while other sources of periodicity, including seasonally varying transmissibility
may appear more likely explanations of varicella periodicity, outcomes from our model
appear to accord with data on recurrence and reinfection, suggesting a role for these
processes in enhanced models of VZV transmission.
We must acknowledge substantial limitations in relation to the realism exhibited by
our model. It is generally accepted that age-dependent transmission is important in the
context of varicella and HZ transmission and disease incidence but we do not include
this here. Instead we include only a basic demographic process involving a constant
birth/death rateμ as our approach aimed to isolate the impacts of recurrence and reinfec-
tion in a prototype model via minimising the total number of model parameters (a similar
approach was used in, for example, [18]). A more realistic model would incorporate age-
dependent transmission rates and age-dependent risks of HZ reactivation, with potential
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to consider more subtle differences such as gender related risks of disease. Other models
also implement the assumption that breakthrough varicella is milder and less contagious
than primary infection, based on experience with vaccine trials and implementation. Con-
sideration of the impact of vaccination is also ignored here, given that the focus is on
qualitative behaviours in a simple model. Note that as a result of the mentioned limita-
tions, varicella incidence in the entire population produced by our model is higher than
zoster incidence (see Figure 3). This is typical in the absence of vaccination, while in
the post-vaccination period one often observes zoster incidence increasing and exceed-
ing that of varicella (see, for example, [17,38]). The increase in zoster could be further
facilitated by the ageing of population as discussed in [23].
Periodicity of varicella and HZ as such do not seem to be of major consequences to pub-
lic health. This is partly because periodicity of zoster has yet to be firmly substantiated.
For example, an Italian study found an annual cycle in HZ notifications with significant
peaks in May-June [22]. On the other hand, HZ periodicity was not detected by a num-
ber of population-based studies and long-term analyses of data [24,25]. However, there
has been a steady interest in gaining a better understanding of the reasons for VZV
reactivation - should that be successful, practical implications are likely to follow. It is
possible that seasonal variations in the incidence of immunologically related diseases may
be related to circannual variations in immune response [39] or, in the case of HZ, to the
effects of ultraviolet (UV) [40]. We suggest that varicella and zoster periodicity may be
potentially explained solely by VZV natural history and including clinical reinfection with
varicella and the possibility that only a limited exposure is needed for immune boosting
in modelling studies may result in more accurate predictions.
Additional file
Additional file 1: Supplementary materials. Hopf curves for all parameter pairs (78 figures).
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